Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.

BREAKING NEWS

BREAKING NEWS

GSK's Nucala wins European panel thumbs-up for self-administration

GSK's Nucala wins European panel thumbs-up for self-administration
FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera -
Copyright
Loriene Perera(Reuters)
Text size Aa Aa

(Reuters) – GlaxoSmithKline said on Tuesday it had won marketing approval from a European Medicines Agency (EMA) panel for its Nucala drug to be self-administered to treat severe asthma.

EMA’s human medicines committee (CHMP) cleared the drug mepolizumab, branded as Nucala, and recommended two new methods for administering the drug to patients with severe eosinophils asthma.

(Reporting by Justin George Varghese in Bengaluru; editing by Patrick Graham)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.